Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study
DOI:
https://doi.org/10.2340/1651-226X.2025.43794Keywords:
Prostatic Neoplasms, Castration-Resistant, Radium-223, Observational study, Metastasis, Survival AnalysisAbstract
Background: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated. In Europe, radium-223 is restricted to third line treatment or later for chemotherapy-eligible men, although studies suggest greater benefit with earlier use. In this nationwide, population-based study, we investigated radium-223 use in Sweden and analyzed the association between line of treatment and overall survival.
Methods: Men with mCRPC who started radium-223 in 2014-2020 were identified in national registers. The Kaplan-Meier method was used to estimate survival. The association between line of treatment and survival was analyzed with Cox regression and presented as adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). A subgroup with at least three mCRPC treatment lines was similarly analyzed.
Results: 1,133 men were included. Median overall survival was 13.9 months (95% CI 13.0-14.5). Later line of radium-223 treatment was associated with shorter survival; with first line as reference, aHR for death for second line was 1.34 (95% CI 1.12-1.59) and for third line 1.55 (1.29-1.87). The opposite was observed for 596 men with at least three lines of mCRPC treatment: aHR for second line was 0.80 (0.59-1.08) and for third line 0.78 (0.59-1.03).
Interpretation: Survival after start of radium-223 in Sweden was comparable to pivotal trials, suggesting effective use. Our overall results do not suggest a better effect of radium-223 in first versus later mCRPC treatment lines but rather emphasize the value of a randomized controlled trial to more definitely determine the optimal timing of radium-223 treatment.
Downloads
References
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.
https://doi.org/10.1056/NEJMoa1213755 DOI: https://doi.org/10.1056/NEJMoa1213755
van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives. Clin Genitourin Cancer. 2019;17(2):79–87.
https://doi.org/10.1016/j.clgc.2018.11.008 DOI: https://doi.org/10.1016/j.clgc.2018.11.008
Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, et al. The contemporary use of radium-223 in metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2018;16(1):e223–31.
https://doi.org/10.1016/j.clgc.2017.08.020 DOI: https://doi.org/10.1016/j.clgc.2017.08.020
Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin M-E, Kungel TM, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update. J Clin Oncol. 2025;43(20):2311–34.
https://doi.org/10.1200/JCO-25-00007 DOI: https://doi.org/10.1200/JCO-25-00007
Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164–82.
https://doi.org/10.1016/j.eururo.2024.04.010 DOI: https://doi.org/10.1016/j.eururo.2024.04.010
Shore N, Carles J, McDermott R, Agarwal N, Tombal B. Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2024;11:1460212.
https://doi.org/10.3389/fmed.2024.1460212 DOI: https://doi.org/10.3389/fmed.2024.1460212
Morris MJ, Wit RD, Vogelzang NJ, Tagawa ST, Higano CS, Hamberg P. A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA. J Clin Oncol. 2021;39(15_Suppl):TPS5091.
https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS5091 DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS5091
Fizazi K, Alba AGd, Mustafa Ö, Skoneczna IA, Krissel H, Uema D, et al. Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study. J Clin Oncol. 2021;39(15_suppl):TPS5093.
https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS5093 DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS5093
Gillessen S, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333/PEACE-3. Ann Oncol. 2024;35:S1254.
https://doi.org/10.1016/j.annonc.2024.08.2307 DOI: https://doi.org/10.1016/j.annonc.2024.08.2307
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.
https://doi.org/10.1056/NEJMsb1609216 DOI: https://doi.org/10.1056/NEJMsb1609216
Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406.
https://doi.org/10.1016/S1470-2045(14)70474-7 DOI: https://doi.org/10.1016/S1470-2045(14)70474-7
O’Sullivan JM, McKay RR, Rahbar K, Fizazi K, George DJ, Tombal B, et al. Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2022;9:fmed-09-1070392.
https://doi.org/10.3389/fmed.2022.1070392 DOI: https://doi.org/10.3389/fmed.2022.1070392
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, et al. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022;25(2):306–13.
https://doi.org/10.1038/s41391-021-00488-0 DOI: https://doi.org/10.1038/s41391-021-00488-0
EMA restricts the use of prostate cancer medicine Xofigo [Internet]. London: European Medicines Agency; 2018 [press release]. [Cited date: 15 April 2024] Available from: https://www.ema.europa.eu/en/medicines/human/referrals/xofigo
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408–19.
https://doi.org/10.1016/S1470-2045(18)30860-X DOI: https://doi.org/10.1016/S1470-2045(18)30860-X
Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) trial. Eur J Nucl Med Mol Imaging. 2023;50(5):1487–98.
https://doi.org/10.1007/s00259-022-06082-3 DOI: https://doi.org/10.1007/s00259-022-06082-3
O’Sullivan JM, Heinrich D, James ND, Nilsson S, Ost P, Parker CC, et al. The case against the European Medicines Agency’s change to the label for radium-223 for the treatment of metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(3):e51–2.
https://doi.org/10.1016/j.eururo.2018.11.003 DOI: https://doi.org/10.1016/j.eururo.2018.11.003
Van den Wyngaert T, Tombal B. The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label? Q J Nucl Med Mol Imaging. 2019;63(2):170–82.
https://doi.org/10.23736/S1824-4785.19.03205-9 DOI: https://doi.org/10.23736/S1824-4785.19.03205-9
Heidenreich A, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Carles J, et al. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer. 2019;19(1):12.
https://doi.org/10.1186/s12885-018-5203-y DOI: https://doi.org/10.1186/s12885-018-5203-y
Jarvis P, Ho A, Sundram F. Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway. Nucl Med Commun. 2021;42(3):332–6.
https://doi.org/10.1097/MNM.0000000000001325 DOI: https://doi.org/10.1097/MNM.0000000000001325
Kuppen MC, Westgeest HM, van der Doelen MJ, van den Eertwegh AJ, Coenen JL, Aben KK, et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncol. 2020;16(19):1371–84.
https://doi.org/10.2217/fon-2020-0039 DOI: https://doi.org/10.2217/fon-2020-0039
Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of radium-223 treatment of castration-resistant prostate cancer based on the burden of skeletal metastasis and clinical parameters. Oncologist. 2023;28(3):246–51.
https://doi.org/10.1093/oncolo/oyac245 DOI: https://doi.org/10.1093/oncolo/oyac245
Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65(2):270–3.
https://doi.org/10.1016/j.eururo.2013.10.055 DOI: https://doi.org/10.1016/j.eururo.2013.10.055
O’Sullivan JM, Abramowitz E, Sierra-Scacalossi L. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary. Future Oncol. 2023;19(15):1021–8.
https://doi.org/10.2217/fon-2022-1296 DOI: https://doi.org/10.2217/fon-2022-1296
Lozano R, Almagro E, Castro E. Relevance of radium-223 in hospital clinical practice from a medical oncologist point of view. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019;38(2):106–11.
https://doi.org/10.1016/j.remnie.2019.02.001 DOI: https://doi.org/10.1016/j.remnie.2019.02.001
Gómez-Veiga F, Álvarez-Ossorio JL, Carballido-Rodríguez J, Juárez-Soto A, Rodríguez-Antolín A, Cozar-Olmo JM. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: a window of opportunity. Actas Urol Esp (Engl Ed). 2018;42(10):616–24. DOI: https://doi.org/10.1016/j.acuroe.2018.10.005
https://doi.org/10.1016/j.acuro.2018.05.004 DOI: https://doi.org/10.1016/j.acuro.2018.05.004
Maruzzo M, Basso U, Borsatti E, Evangelista L, Alongi F, Caffo O, et al. Results from a large, multicenter, retrospective analysis on radium223 use in metastatic castration-resistant prostate cancer (mCRPC) in the Triveneto Italian Region. Clin Genitourin Cancer. 2019;17(1):e187–94.
https://doi.org/10.1016/j.clgc.2018.10.013 DOI: https://doi.org/10.1016/j.clgc.2018.10.013
Caffo O, Frantellizzi V, Tucci M, Galli L, Monari F, Baldari S, et al. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. Eur J Nucl Med Mol Imaging. 2020;47(11):2633–8.
https://doi.org/10.1007/s00259-020-04796-w
Stattin P, Westerberg M, Lissbrant IF, Eriksson MH, Kjellman A, Ullén A, et al. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2023;21(1):107.e1–9. DOI: https://doi.org/10.1016/j.clgc.2022.09.002
https://doi.org/10.1007/s00259-020-04796-w DOI: https://doi.org/10.1007/s00259-020-04796-w
Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956–67.
https://doi.org/10.1093/ije/dys068 DOI: https://doi.org/10.1093/ije/dys068
Franck Lissbrant I, Hjälm Eriksson M, Lambe M, Törnblom M, Stattin P. Set-up and preliminary results from the patient-overview prostate cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227–34.
https://doi.org/10.1080/21681805.2020.1756402 DOI: https://doi.org/10.1080/21681805.2020.1756402
Fallara G, Alverbratt C, Garmo H, Vikman H, Hjelm Eriksson M, Lissbrant IF, et al. Time on treatment with abiraterone and enzalutamide in the patient-overview prostate cancer in the National Prostate Cancer Register of Sweden. Acta Oncol. 2021;60(12):1589–96.
https://doi.org/10.1080/0284186X.2021.1978539 DOI: https://doi.org/10.1080/0284186X.2021.1978539
Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, et al. Pre-existing castration-resistant prostate cancer–like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022;81(5):446–55.
https://doi.org/10.1016/j.eururo.2021.12.039 DOI: https://doi.org/10.1016/j.eururo.2021.12.039
Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, et al. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urol Oncol. 2014;32(1):36.e27–34.
https://doi.org/10.1016/j.urolonc.2013.02.015 DOI: https://doi.org/10.1016/j.urolonc.2013.02.015
Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(2):252–60.
https://doi.org/10.1038/s41391-018-0095-0 DOI: https://doi.org/10.1038/s41391-018-0095-0
Zist A, Amir E, Ocana AF, Seruga B. Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. Radiol Oncol. 2015;49(4):402–8.
https://doi.org/10.1515/raon-2015-0038 DOI: https://doi.org/10.1515/raon-2015-0038
McKay RR, Silver R, Bhak RH, Korves C, Cheng M, Appukkuttan S, et al. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. 2021;24(1):210–19.
https://doi.org/10.1038/s41391-020-00271-7 DOI: https://doi.org/10.1038/s41391-020-00271-7
Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, et al. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine. 2023;60:101993.
https://doi.org/10.1016/j.eclinm.2023.101993 DOI: https://doi.org/10.1016/j.eclinm.2023.101993
Hyväkkä A, Kääriäinen OS, Utriainen T, Löyttyniemi E, Mattila K, Reinikainen P, et al. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: a real-world evidence multicenter study. Cancer Med. 2023;12(4):4064–76.
https://doi.org/10.1002/cam4.5262 DOI: https://doi.org/10.1002/cam4.5262
Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090–7.
https://doi.org/10.1093/annonc/mdx044 DOI: https://doi.org/10.1093/annonc/mdx044
Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–16.
https://doi.org/10.1016/S1470-2045(16)30173-5 DOI: https://doi.org/10.1016/S1470-2045(16)30173-5
Peters N, Bambury RM, Power DG, McCarthy L, Lyons C, Kelly P, et al. Radium-223 in the treatment of metastatic castrate-resistant prostate cancer. Ir Med J. 2022;115(2):536.
Dizdarevic S, Jessop M, Begley P, Main S, Robinson A. (223)Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. Eur J Nucl Med Mol Imaging. 2018;45(13):2264–73.
https://doi.org/10.1007/s00259-018-4083-3 DOI: https://doi.org/10.1007/s00259-018-4083-3
Parikh S, Murray L, Kenning L, Bottomley D, Din O, Dixit S, et al. Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer. Clin Oncol. 2018;30(9):548–55.
https://doi.org/10.1016/j.clon.2018.06.004 DOI: https://doi.org/10.1016/j.clon.2018.06.004
Sartor O, Appukkuttan S, Weiss J, Tsao C-K. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings. Prostate. 2021;81(10):657–66.
https://doi.org/10.1002/pros.24143 DOI: https://doi.org/10.1002/pros.24143
Cheng S, Arciero V, Goldberg H, Tajzler C, Manganaro A, Kozlowski N, et al. Population-based analysis of the use of radium-223 for bone-metastatic castration-resistant prostate cancer in Ontario, and of factors associated with treatment completion and outcome. Cancer Manag Res. 2019;11:9307–19.
https://doi.org/10.2147/CMAR.S213051 DOI: https://doi.org/10.2147/CMAR.S213051
Buscombe J, Gillett D, Bird N, Powell A, Heard S, Aloj L. Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases. World J Nucl Med. 2021;20(2):139–44.
https://doi.org/10.4103/wjnm.WJNM_74_20 DOI: https://doi.org/10.4103/wjnm.WJNM_74_20
Miyoshi Y, Tsutsumi S, Yasui M, Kawahara T, Uemura K-i, Hayashi N, et al. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. World J Urol. 2021;39(9):3323–8.
https://doi.org/10.1007/s00345-021-03639-z DOI: https://doi.org/10.1007/s00345-021-03639-z
Dadhania S, Alonzi R, Douglas S, Gogbashian A, Hughes R, Dalili D, et al. Single-centre experience of use of radium 223 with clinical outcomes based on number of cycles and bone marrow toxicity. Anticancer Res. 2018;38(9):5423–7.
https://doi.org/10.21873/anticanres.12873 DOI: https://doi.org/10.21873/anticanres.12873
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Charlotte Alverbratt, Fredrik Sandin, Viktor Kolmbäck, Hans Garmo, Ola Bratt, Ingela Franck Lissbrant
This work is licensed under a Creative Commons Attribution 4.0 International License.
